Affiliation:
1. Ethox Centre University of Oxford Oxford UK
2. Institute of Medical Genetics Cardiff University Cardiff UK
3. Institute of Interdisciplinary Research on Social Issues University of Sorbonne Paris Nord Bobigny France
4. Ethics in Medicine University of Augsburg Augsburg Germany
Abstract
AbstractNon‐invasive prenatal testing (NIPT) is provided in the private and public sectors worldwide as a first‐ or second‐tier test. In England and France, NIPT is fully funded and offered as a contingent strategy with different probability cut‐offs (1:150 and 1:1000). These different approaches to define the target population for NIPT have implications for how women experience their antenatal care. The paper explores and compares the perceptions and difficulties of women in England and France who took NIPT as a second‐tier screening test. It is based on a semi‐structured qualitative interview study with 17 women in England and France conducted between September 2021 and May 2022. The interviews were cross‐analyzed using thematic analysis. Our findings show that most women express a preference for the offer of NIPT as a first‐line screening test. Some issues with the contingent model, related to the access to information and termination of pregnancy (TOP), the disparities of NIPT uptake, and risks of generating anxiety with combined first‐trimester screening (cFTS), could be addressed by a universal strategy for T21, T13, and T18. Nevertheless, this strategy could present some challenges for genetic counseling due to: women's understanding and expectations of NIPT; adequate information and counseling about the scope and limits of NIPT; concerns about the routinization of NIPT in the first‐line offer; limitations and uncertainties associated with the provision of expanded NIPT in France; the remaining importance of other screening tests; and associated costs.
Funder
Economic and Social Research Council
Reference49 articles.
1. Agence de la biomédecine. (2021).Du don à la vie. Rapport annuel 2021.https://rapport‐annuel.agence‐biomedecine.fr/
2. The effect of stress and anxiety associated with maternal prenatal diagnosis on feto‐maternal attachment;Allison S. J.;BMC Women's Health,2011
3. Ameli. Assurance maladie. (2023).Comprendre l'interruption médicalisée de grossesse.https://www.ameli.fr/assure/sante/themes/img/comprendre‐img
4. Article L2212‐1 du Code de la Santé Publique.2022.https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000031930136/
5. Association des Cytogénéticiens de Langue Française. (2020).Recommandations sur la conduite à tenir devant l'identification d'anomalies chromosomiques fœtales autres que les trisomies 13 18 et 21 par l'étude de l'ADN libre circulant (ADNlc).http://www.eaclf.org/docs/Reco%20DPNI%20WG.pdf
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献